Correlation Between Amicus Therapeutics and Eyepoint Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Eyepoint Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Eyepoint Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Amicus Therapeutics and Eyepoint Pharmaceuticals, you can compare the effects of market volatilities on Amicus Therapeutics and Eyepoint Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Eyepoint Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Eyepoint Pharmaceuticals.

Diversification Opportunities for Amicus Therapeutics and Eyepoint Pharmaceuticals

0.49
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Amicus and Eyepoint is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Eyepoint Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyepoint Pharmaceuticals and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Eyepoint Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyepoint Pharmaceuticals has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Eyepoint Pharmaceuticals go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Eyepoint Pharmaceuticals

Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Eyepoint Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Amicus Therapeutics is 2.28 times less risky than Eyepoint Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Eyepoint Pharmaceuticals is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  910.00  in Eyepoint Pharmaceuticals on September 13, 2024 and sell it today you would lose (85.00) from holding Eyepoint Pharmaceuticals or give up 9.34% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Amicus Therapeutics  vs.  Eyepoint Pharmaceuticals

 Performance 
       Timeline  
Amicus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.
Eyepoint Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Eyepoint Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Amicus Therapeutics and Eyepoint Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Amicus Therapeutics and Eyepoint Pharmaceuticals

The main advantage of trading using opposite Amicus Therapeutics and Eyepoint Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Eyepoint Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyepoint Pharmaceuticals will offset losses from the drop in Eyepoint Pharmaceuticals' long position.
The idea behind Amicus Therapeutics and Eyepoint Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements